Symbiotec Pharmalab IPO Logo

Symbiotec Pharmalab IPO

Live Updates, GMP, Subscription Data, and Financial Details

IPO Overview

Listed
Dates Aug 24 to Aug 27 2026
Price Band ₹938 - 988
Current GMP ₹988 (0.00%)
Subscription 75.08 times

IPO Details

IPO Date
24 to 27 Aug, 2026
Listing Date
Tue, Sep 1, 2026
Face Value
₹ 2 per share
Price Band
₹938 to ₹988
Issue Price
₹988 per share
Lot Size
15 Shares
Sale Type
Fresh capital cum OFS
Issue Type
Bookbuilding IPO
Listing At
BSE, NSE
Employee Discount
₹ 90.00
Total Issue Size
1,77,86,442 shares (agg. up to ₹ 1,757 Cr)
Fresh Issue
15,21,261 shares (agg. up to ₹ 150 Cr)
Offer for Sale
1,62,65,181 shares of ₹ 2 (agg. up to ₹ 1,607 Cr)
Share Holding Pre Issue
6,27,34,851 shares
Share Holding Post Issue
6,42,56,112 shares

IPO Subscription Details

Anchor
1
QIB (Ex Anchor)
181.20
NII
77.56
bNII (> ₹10L)
87.34
sNII (< ₹10L)
58.01
Retail
13.69
Employees
16.32
Total **
75.08

Day Wise Sub

DayAug 2 4 (Day 1)
QIB (Ex Anchor)0.37
NII1.10
NII (> ₹10L)0.82
NII (< ₹10L)1.66
Retail1.01
EMP1.65
Total0.85
DayAug 2 5 (Day 2)
QIB (Ex Anchor)0.57
NII3.16
NII (> ₹10L)2.59
NII (< ₹10L)4.30
Retail2.22
EMP3.19
Total1.95
DayAug 2 6 (Day 3)
QIB (Ex Anchor)0.62
NII12.86
NII (> ₹10L)11.90
NII (< ₹10L)14.78
Retail5.38
EMP6.25
Total5.62
DayAug 2 7 (Day 4)
QIB (Ex Anchor)181.20
NII77.56
NII (> ₹10L)87.34
NII (< ₹10L)58.01
Retail13.69
EMP16.32
Total75.08

Day Wise GMP

GMP Date01-09-2026
IPO Price988
GMP185 (18.72%)
Est. Listing Price1173
GMP Date31-08-2026
IPO Price988
GMP185 (18.72%)
Est. Listing Price1173
GMP Date30-08-2026
IPO Price988
GMP240 (24.29%)
Est. Listing Price1228
GMP Date29-08-2026
IPO Price988
GMP240 (24.29%)
Est. Listing Price1228
GMP Date28-08-2026
IPO Price988
GMP265 (26.82%)
Est. Listing Price1253
GMP Date27-08-2026
IPO Price988
GMP270 (27.33%)
Est. Listing Price1258
GMP Date26-08-2026
IPO Price988
GMP285 (28.85%)
Est. Listing Price1273
GMP Date25-08-2026
IPO Price988
GMP352 (35.63%)
Est. Listing Price1340
GMP Date24-08-2026
IPO Price988
GMP335 (33.91%)
Est. Listing Price1323
GMP Date23-08-2026
IPO Price988
GMP409 (41.40%)
Est. Listing Price1397
GMP Date22-08-2026
IPO Price988
GMP410 (41.50%)
Est. Listing Price1398
GMP Date21-08-2026
IPO Price988
GMP345 (34.92%)
Est. Listing Price1333
GMP Date20-08-2026
IPO Price988
GMP300 (30.36%)
Est. Listing Price1288
GMP Date19-08-2026
IPO Price988
GMP220 (22.27%)
Est. Listing Price1208

IPO Important Dates

IPO Open
Mon, Aug 24, 2026
IPO Close
Thu, Aug 27, 2026
Allotment
Fri, Aug 28, 2026
Refund
Mon, Aug 31, 2026
Credit of Shares
Mon, Aug 31, 2026
Listing
Tue, Sep 1, 2026

IPO Lot Size

ApplicationRetail (Min)
Lots1
Shares15
Amount₹14,820
ApplicationRetail (Max)
Lots13
Shares195
Amount₹1,92,660
ApplicationS-HNI (Min)
Lots14
Shares210
Amount₹2,07,480
ApplicationS-HNI (Max)
Lots67
Shares1,005
Amount₹9,92,940
ApplicationB-HNI (Min)
Lots68
Shares1,020
Amount₹10,07,760

Financial Information

Period EndedAssets
31 Mar 20261,780.79
31 Mar 20251,579.65
31 Mar 20241,294.79
Period EndedTotal Income
31 Mar 2026872.26
31 Mar 2025755.98
31 Mar 2024723.33
Period EndedProfit After Tax
31 Mar 2026109.90
31 Mar 202596.79
31 Mar 2024100.06
Period EndedEBITDA
31 Mar 2026231.97
31 Mar 2025206.11
31 Mar 2024177.04
Period EndedNET Worth
31 Mar 20261,158.64
31 Mar 2025821.15
31 Mar 2024720.68
Period EndedReserves and Surplus
31 Mar 20261,145.95
31 Mar 2025810.03
31 Mar 2024709.54
Period EndedTotal Borrowing
31 Mar 2026387.91
31 Mar 2025540.92
31 Mar 2024247.21

Key Performance Indicator

ROE
11.19%
ROCE
11.56%
RoNW
9.48%
PAT Margin
12.60%
EBITDA Margin
26.59%
NAV
184.69
Price to Book Value
5.35

IPO Reservation

QIB
88,76,516
− Anchor Investor
53,25,909
− QIB (Ex. Anchor)
35,50,607
NII (HNI)
26,62,956
− bNII > ₹10L
17,75,304
− sNII < ₹10L
8,87,652
Retail
62,13,563
Employee
33,407
Total
1,77,86,442

Information about company

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions. With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations. As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres. Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards. Competitive Strengths:

Objectives of IPO

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: #: Issue Objects 1: Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company 2: General Corporate Purposes 3: Issue Expenses : Total

Disclaimer

All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application. No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever Please read all Tearms and conditions , and agree to use the App